Current low global SARS-CoV-2 circulation, with test positivity around 3% and minimal hospitalizations or deaths reported to the WHO through mid-2026, underpins the 96.2% market-implied odds against a new coronavirus pandemic this year. Circulating Omicron sublineages such as XFG and JN.1 show no evidence of heightened severity or public health risk relative to prior strains, consistent with sustained population immunity and routine surveillance from agencies like the CDC. Seasonal upticks remain localized and manageable without crossing epidemic thresholds. A realistic shift could occur if a novel betacoronavirus with enhanced transmissibility and virulence emerges via zoonotic spillover or recombination, though ongoing genomic monitoring has detected no such development to date.